Global Androgen Deprivation Therapy (ADT) Market Size study, by Drug Class (Antiandrogens, LHRH Agonists, LHRH Antagonist, Others), by Route of Administration (Oral, Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Regional Forecasts 2019-2026

  • Report Id: BIZ 3049
  • Published Date: February, 2020
  • No of Pages: 200
  • Format: Electronic (PDF)
  • Publisher: Bizwit Research & Consulting LLP
  • Category:

Global Androgen Deprivation Therapy (ADT) Market is valued approximately at USD XX billion in 2018 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2019-2026. Androgen deprivation therapy (ADT) is a type of antihormone therapy which is primarily utilized in the cure of prostate cancer. Prostate cancer cells typically requires androgen hormones such as testosterone to grow. The use of androgen deprivation therapy reduces the level of androgen hormones, with surgery or drug delivery to prevent the prostate cells from rising. Various studies have determined that ADT has shown the benefits in patients with metastatic disease, and as an addition to radiation therapy in patients with locally developed disease, including those with adverse intermediate-risk or extreme-risk localized disease. Surging incidences of prostate cancer, rising male geriatric population, along with increasing government efforts to implement & conduct programs for creating of awareness of screening tests such as Prostate-Specific Antigen (PSA) blood tests are the few factor responsible for high CAGR of the market over the forecast period. For instance, according to the GLOBOCAN 2018 estimates in 2018, about 1,276,106 new cases of prostate cancer were registered worldwide, representing 7.1% of all cancers in men. Similarly, As per the Canadian Cancer Society, it is estimated that 22,900 men will be diagnosed with prostate cancer in 2019 and this represents 20% of all new cancer cases in men in 2019. Moreover, technological advancement in screening & diagnostic tests is one of the major factor projected to create lucrative growth opportunities to the market growth in the forecasting years. However, side effects associated with ADT is the major factor restraining the growth of global Androgen Deprivation Therapy (ADT) market during the forecast period of 2019-2026.

The regional analysis of global Androgen Deprivation Therapy (ADT) Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the surging investments in R&D for the development of newer immunotherapies and targeted drug therapies to treat prostate cancer in the region. However, Asia-Pacific is anticipated to exhibit highest growth rate / CAGR over the forecast period due to rising awareness among patient towards the treatment of prostate cancer. Further, increasing number of government programs to promote the adoption of ADT, would also create a lucrative opportunity for the growth of the market in the Asia-Pacific region.

Major market player included in this report are:
Pfizer Inc.
Astellas Pharma Inc.
Johnson & Johnson
Novartis International AG
Veru Inc.
Sanofi S.A.
GlaxoSmithKline plc
Bayer AG
Orion Corporation
AstraZeneca Plc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Class:
Antiandrogens
LHRH Agonists
LHRH Antagonist
Others
By Route of Administration:
Oral
Injectable
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region:
North America
U.S.
Canada
Europe
UK
Germany
Asia Pacific
China
India
Japan
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2016, 2017
Base year – 2018
Forecast period – 2019 to 2026

Target Audience of the Global Androgen Deprivation Therapy (ADT) Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies:

Pfizer Inc.
Astellas Pharma Inc.
Johnson & Johnson
Novartis International AG
Veru Inc.
Sanofi S.A.
GlaxoSmithKline plc
Bayer AG
Orion Corporation
AstraZeneca Plc.

Countries:

U.S.
Canada
UK
Germany
France
China
India
Japan
Brazil
Mexico

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2017-2026 (USD Billion)
1.2.1. Androgen Deprivation Therapy (ADT) Market, by Drug Class, 2017-2026 (USD Billion)
1.2.2. Androgen Deprivation Therapy (ADT) Market, by Route of Administration, 2017-2026 (USD Billion)
1.2.3. Androgen Deprivation Therapy (ADT) Market, by Distribution Channel, 2017-2026 (USD Billion)
1.2.4. Androgen Deprivation Therapy (ADT) Market, by Region, 2017-2026 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Androgen Deprivation Therapy (ADT) Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Androgen Deprivation Therapy (ADT) Market Dynamics
3.1. Androgen Deprivation Therapy (ADT) Market Impact Analysis (2018-2026)
3.1.1. Market Drivers
3.1.2. Market Challenges
3.1.3. Market Opportunities
Chapter 4. Global Androgen Deprivation Therapy (ADT) Market Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model (2016-2026)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global Androgen Deprivation Therapy (ADT) Market, by Drug Class
5.1. Market Snapshot
5.2. Global Androgen Deprivation Therapy (ADT) Market by Drug Class, Performance – Potential Analysis
5.3. Global Androgen Deprivation Therapy (ADT) Market Estimates & Forecasts by Drug Class 2016-2026 (USD Billion)
5.4. Androgen Deprivation Therapy (ADT) Market, Sub Segment Analysis
5.4.1. Antiandrogens
5.4.2. LHRH Agonists
5.4.3. LHRH Antagonist
5.4.4. Others
Chapter 6. Global Androgen Deprivation Therapy (ADT) Market, by Route of Administration
6.1. Market Snapshot
6.2. Global Androgen Deprivation Therapy (ADT) Market by Route of Administration, Performance – Potential Analysis
6.3. Global Androgen Deprivation Therapy (ADT) Market Estimates & Forecasts by Route of Administration, 2016-2026 (USD Billion)
6.4. Androgen Deprivation Therapy (ADT) Market, Sub Segment Analysis
6.4.1. Oral
6.4.2. Injectable
Chapter 7. Global Androgen Deprivation Therapy (ADT) Market, by Distribution Channel
7.1. Market Snapshot
7.2. Global Androgen Deprivation Therapy (ADT) Market by Distribution Channel, Performance – Potential Analysis
7.3. Global Androgen Deprivation Therapy (ADT) Market Estimates & Forecasts by Distribution Channel, 2016-2026 (USD Billion)
7.4. Androgen Deprivation Therapy (ADT) Market, Sub Segment Analysis
7.4.1. Hospital Pharmacies
7.4.2. Retail Pharmacies
7.4.3. Online Pharmacies
Chapter 8. Global Androgen Deprivation Therapy (ADT) Market, Regional Analysis
8.1. Androgen Deprivation Therapy (ADT) Market, Regional Market Snapshot
8.2. North America Androgen Deprivation Therapy (ADT) Market
8.2.1. U.S. Androgen Deprivation Therapy (ADT) Market
8.2.1.1. Drug Class breakdown estimates & forecasts, 2016-2026
8.2.1.2. Route of Administration breakdown estimates & forecasts, 2016-2026
8.2.1.3. Distribution Channel breakdown estimates & forecasts, 2016-2026
8.2.2. Canada Androgen Deprivation Therapy (ADT) Market
8.3. Europe Androgen Deprivation Therapy (ADT) Market Snapshot
8.3.1. U.K. Androgen Deprivation Therapy (ADT) Market
8.3.2. Germany Androgen Deprivation Therapy (ADT) Market
8.3.3. Rest of Europe Androgen Deprivation Therapy (ADT) Market
8.4. Asia-Pacific Androgen Deprivation Therapy (ADT) Market Snapshot
8.4.1. China Androgen Deprivation Therapy (ADT) Market
8.4.2. India Androgen Deprivation Therapy (ADT) Market
8.4.3. Japan Androgen Deprivation Therapy (ADT) Market
8.4.4. Rest of Asia Pacific Androgen Deprivation Therapy (ADT) Market
8.5. Latin America Androgen Deprivation Therapy (ADT) Market Snapshot
8.5.1. Brazil Androgen Deprivation Therapy (ADT) Market
8.5.2. Mexico Androgen Deprivation Therapy (ADT) Market
8.6. Rest of The World Androgen Deprivation Therapy (ADT) Market
Chapter 9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. Pfizer Inc.
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject To Data Availability)
9.2.1.4. Product Summary
9.2.1.5. Recent Developments
9.2.2. Astellas Pharma Inc.
9.2.3. Johnson & Johnson
9.2.4. Novartis International AG
9.2.5. Veru Inc.
9.2.6. Sanofi S.A.
9.2.7. GlaxoSmithKline plc
9.2.8. Bayer AG
9.2.9. Orion Corporation
9.2.10. AstraZeneca Plc.
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption

TABLE 1. LIST OF SECONDARY SERVICES, USED IN THE STUDY OF GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET
TABLE 2. LIST OF PRIMARY SERVICES, USED IN THE STUDY OF GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET
TABLE 3. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET, REPORT SCOPE
TABLE 4. YEARS CONSIDERED FOR THE STUDY
TABLE 5. EXCHANGE RATES CONSIDERED
TABLE 6. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY REGION 2016-2026 (USD BILLION)
TABLE 7. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY DRUG CLASS 2016-2026 (USD BILLION)
TABLE 8. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY ROUTE OF ADMINISTRATION 2016-2026 (USD BILLION)
TABLE 9. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY DISTRIBUTION CHANNEL 2016-2026 (USD BILLION)
TABLE 10. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 11. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 12. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 13. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 14. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 15. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 16. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 17. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 18. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 19. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 20. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 21. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 22. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 23. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 24. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 25. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 26. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 27. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET BY REGION, ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 28. U.S. ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 29. U.S. ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 30. U.S. ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 31. U.S. ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 32. CANADA ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 33. CANADA ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 34. CANADA ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 35. CANADA ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 36. UK ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 37. UK ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 38. UK ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 39. UK ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 40. GERMANY ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 41. GERMANY ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 42. GERMANY ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 43. GERMANY ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 44. ROE ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 45. ROE ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 46. ROE ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 47. ROE ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 48. CHINA ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 49. CHINA ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 50. CHINA ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 51. CHINA ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 52. INDIA ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 53. INDIA ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 54. INDIA ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 55. INDIA ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 56. JAPAN ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 57. JAPAN ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 58. JAPAN ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 59. JAPAN ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 60. ROAPAC ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 61. ROAPAC ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 62. ROAPAC ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 63. ROAPAC ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 64. BRAZIL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 65. BRAZIL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 66. BRAZIL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 67. BRAZIL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 68. MEXICO ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 69. MEXICO ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 70. MEXICO ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 71. MEXICO ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 72. ROLA ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 73. ROLA ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 74. ROLA ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 75. ROLA ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 76. ROW ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS, 2016-2026 (USD BILLION)
TABLE 77. ROW ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 78. ROW ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
TABLE 79. ROW ANDROGEN DEPRIVATION THERAPY (ADT) MARKET ESTIMATES & FORECASTS BY SEGMENT 2016-2026 (USD BILLION)
FIG 1. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET, RESEARCH METHODOLOGY
FIG 2. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET, MARKET ESTIMATION TECHNIQUES
FIG 3. GLOBAL MARKET SIZE ESTIMATES & FORECAST METHODS
FIG 4. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET, KEY TRENDS 2018
FIG 5. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET, GROWTH PROSPECTS 2019-2026
FIG 6. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET, PORTERS 5 FORCE MODEL
FIG 7. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET, PEST ANALYSIS
FIG 8. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET, VALUE CHAIN ANALYSIS
FIG 9. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
FIG 10. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
FIG 11. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
FIG 12. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
FIG 13. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
FIG 14. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
FIG 15. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
FIG 16. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
FIG 17. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET BY SEGMENT, 2016 & 2026 (USD BILLION)
FIG 18. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET, REGIONAL SNAPSHOT 2016 & 2026
FIG 19. NORTH AMERICA ANDROGEN DEPRIVATION THERAPY (ADT) MARKET 2016 & 2026 (USD BILLION)
FIG 20. EUROPE ANDROGEN DEPRIVATION THERAPY (ADT) MARKET 2016 & 2026 (USD BILLION)
FIG 21. ASIA PACIFIC ANDROGEN DEPRIVATION THERAPY (ADT) MARKET 2016 & 2026 (USD BILLION)
FIG 22. LATIN AMERICA ANDROGEN DEPRIVATION THERAPY (ADT) MARKET 2016 & 2026 (USD BILLION)
FIG 23. GLOBAL ANDROGEN DEPRIVATION THERAPY (ADT) MARKET, COMPANY MARKET SHARE ANALYSIS (2018)

Choose License Type

Single user
$4,950
Enterprise User
$6,250
Clear

Each market study on Reports Globe will be revised based on COVID-19 impact analysis

How can we help you?

Our salient features

Best Solution

We will help you understand value propositions of various reports across numerous domains and suggest the best possible solution to suffice your research needs.

Customized Research

Our team of analysts and consultants provide assistance for customized research requirements

Max ROI

Guaranteed maximum assistance to help you get your reports at the optimum prices, thereby ensuring maximum returns on investment.

24/7 Support

24X7 availability to help you through the buying process as well as answer any of your doubts.

We've Received Your Request

We Thank You for filling out your requirements. Our sales team will get in touch with you shortly.